Drug
TLL-018 clinical trials
Also written TLL-018.
- studies test it
- 12
- open now
- 4
- in phase 3
- 4
- first study started
- 2022
Keep track of what changes. Save the TLL-018 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
12 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 7
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Hangzhou Highlightll Pharmaceutical Co., Ltd (11) · TLL Pharmaceutical, LLC (1)
Studies
Open first, then newest update. How each study uses TLL-018 is read from its arms, and is right about nine times in ten.
Testing it · 12
- TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDsEnrolling by invitationPhase 2Hangzhou Highlightll Pharmaceutical Co., LtdNCT07748728Written as TLL-018
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic DermatitisNot yet recruitingPhase 2/3Hangzhou Highlightll Pharmaceutical Co., LtdNCT07784816Written as TLL-018 tablets
- A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 AntihistaminesNot yet recruitingPhase 1/2Hangzhou Highlightll Pharmaceutical Co., LtdNCT07665996Written as TLL-018
- A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHsNot yet recruitingPhase 2Hangzhou Highlightll Pharmaceutical Co., LtdNCT07764003Written as TLL-018 tablets
- A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid ArthritisActive, not recruitingPhase 3Hangzhou Highlightll Pharmaceutical Co., LtdNCT06887127Written as TLL-018
- A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDsCompletedPhase 3Hangzhou Highlightll Pharmaceutical Co., LtdNCT06020144Written as TLL-018
- The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque PsoriasisCompletedPhase 2Hangzhou Highlightll Pharmaceutical Co., LtdNCT05772520Written as TLL018 tablets
- A Study of Efficacy and Safety of TLL-018 in CSU ParticipantsActive, not recruitingPhase 3Hangzhou Highlightll Pharmaceutical Co., LtdNCT06396026Written as TLL-018 tablets
- Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.CompletedPhase 1Hangzhou Highlightll Pharmaceutical Co., LtdNCT05373355Written as TLL018 tablets
- Safety and Efficacy of TLL018 in Patients With Plaque PsoriasisCompletedPhase 1Hangzhou Highlightll Pharmaceutical Co., LtdNCT05342428Written as TLL018 tablets
- The Safety and Efficacy of TLL-018 in Active Rheumatoid ArthritisCompletedPhase 2Hangzhou Highlightll Pharmaceutical Co., LtdNCT05133297Written as TLL-018
- Safety and Efficacy Study of TLL018 in the Treatment of Ulcerative ColitisWithdrawnPhase 2TLL Pharmaceutical, LLCNCT05121402Written as TLL018